Integra LifeSciences Holdings Corporation
IART
$13.57
$0.564.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.19% | 4.47% | 1.45% | 1.37% | -2.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.19% | 4.47% | 1.45% | 1.37% | -2.07% |
| Cost of Revenue | 12.27% | 10.50% | 8.72% | 8.62% | 3.67% |
| Gross Profit | 2.26% | 0.70% | -3.00% | -2.95% | -5.45% |
| SG&A Expenses | 11.89% | 11.68% | 6.03% | 4.03% | 0.64% |
| Depreciation & Amortization | 20.92% | 14.94% | 5.11% | 1.36% | -5.99% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.18% | 11.14% | 7.02% | 5.93% | 2.06% |
| Operating Income | -27.38% | -29.68% | -26.44% | -19.69% | -20.18% |
| Income Before Tax | -193.45% | -122.49% | -110.24% | -82.73% | -77.46% |
| Income Tax Expenses | -341.75% | -184.73% | -134.53% | -86.56% | -82.06% |
| Earnings from Continuing Operations | -171.97% | -110.25% | -106.49% | -81.99% | -76.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -171.97% | -110.25% | -106.49% | -81.99% | -76.59% |
| EBIT | -27.38% | -29.68% | -26.44% | -19.69% | -20.18% |
| EBITDA | -10.95% | -15.28% | -16.56% | -9.88% | -13.50% |
| EPS Basic | -174.05% | -110.39% | -107.17% | -81.25% | -75.42% |
| Normalized Basic EPS | -39.21% | -38.41% | -31.23% | -21.11% | -20.32% |
| EPS Diluted | -175.70% | -110.77% | -107.49% | -81.57% | -75.73% |
| Normalized Diluted EPS | -39.15% | -38.27% | -31.08% | -20.91% | -20.11% |
| Average Basic Shares Outstanding | -3.04% | -3.89% | -5.07% | -5.06% | -4.61% |
| Average Diluted Shares Outstanding | -3.13% | -4.12% | -5.29% | -5.30% | -4.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |